A Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Pretreatment Drug Resistance Testing
Viruses · 2024
DOI: 10.3390/v16111713 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Viruses, 2024. Verfasst von Ying Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of HIV/STD Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. Hauptthemen laut MEDLINE: HIV-1, High-Throughput Nucleotide Sequencing, Drug Resistance, Viral, HIV Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Next-generation sequencing (NGS) for HIV drug resistance (DR) testing has an increasing number of applications for the detection of low-abundance drug-resistant variants (LA-DRVs) in regard to its features as a quasi-species. However, there is less information on its detection performance in DR detection with NGS. To determine the feasibility of using NGS technology in LA-DRV detection for HIV-1 pretreatment drug resistance, 80 HIV-infected individuals who had never undergone antiretroviral therapy were subjected to both NGS and Sanger sequencing (SS) in HIV-1 drug resistance testing. The results reported in this study show that NGS exhibits higher sensitivity for drug resistance identification than SS at a 5% detection threshold. NGS showed a better consistency compared with that of SS for both protease inhibitors (PIs) and integrase inhibitors (INSTIs), with a figure amounting to more than 90%, but worse consistency in nucleotide reverse transcriptase inhibitors (NRTIs), with a consistency ranging from only 61.25% to 87.50%. The consistency of non-nucleotide reverse transcriptase inhibitors (NNRTIs) between NGS and SS was around 85%. NGS showed the highest sensitivity of 87.0% at a 5% threshold. The application of NGS technology in HIV-1 genotype resistance detection in different populations infected with HIV requires further documentation and validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of HIV/STD Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
- Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China.
ORCID-Profile: Ying Zhou, Haiyang Hu
Zitieren
APA
Zhou, Y., Ouyang, F., Liu, X., Lu, J., Hu, H., Sun, Q., & Yang, H. (2024). A Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Pretreatment Drug Resistance Testing. Viruses. https://doi.org/10.3390/v16111713
Vancouver
Zhou Y, Ouyang F, Liu X, Lu J, Hu H, Sun Q, et al. A Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Pretreatment Drug Resistance Testing. Viruses. 2024. doi:10.3390/v16111713
BibTeX
@article{Zhou2024,
author = {Zhou, Ying and Ouyang, Fei and Liu, Xiaoyan and Lu, Jing and Hu, Haiyang and Sun, Qi and Yang, Haitao},
title = {A Sensitivity and Consistency Comparison Between Next-Generation Sequencing and Sanger Sequencing in HIV-1 Pretreatment Drug Resistance Testing},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16111713}
}
EUVIMED